Optinose announced that it has appointed R. John Fletcher to its Board of Directors as a Class III director. Prior to founding Fletcher Spaght, John was a Senior Manager at The Boston Consulting Group, advising a broad range of companies in healthcare and high technology industries.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.095 USD | -6.41% | -6.03% | -15.50% |
05-14 | Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
05-14 | Earnings Flash (OPTN) OPTINOSE Posts Q1 Revenue $14.9M, vs. Street Est of $13.7M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.50% | 169M | |
+39.22% | 727B | |
+30.57% | 592B | |
-7.82% | 347B | |
+15.59% | 319B | |
-0.27% | 274B | |
+12.55% | 238B | |
+6.65% | 204B | |
-6.09% | 203B | |
-3.13% | 160B |
- Stock Market
- Equities
- OPTN Stock
- News OptiNose, Inc.
- Optinose Announces Appointment of R. John Fletcher to its Board of Directors as a Class III Director